Results 31 to 40 of about 6,588 (185)

XPR1 downregulation inhibits hepatocellular carcinoma progression by suppressing serine metabolism [PDF]

open access: yesRedox Biology
Xenotropic and polytropic retrovirus receptor 1 (XPR1) is highly expressed in various tumors and is associated with poor clinical prognosis, making it a proposed therapeutic target for cancer. However, the mechanism of XPR1 in tumorigenesis, particularly
Zi-qiang Liao   +8 more
doaj   +2 more sources

PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma [PDF]

open access: yesCell Death and Disease
Osteosarcoma is a bone cancer that has been found to be metabolically dependent on the conversion of glucose to serine through the rate-limiting enzyme 3-phosphoglycerate dehydrogenase (PHGDH).
Toshinao Oyama   +7 more
doaj   +2 more sources

The role of PHGDH in hypoxic adaptation and metabolic reprogramming

open access: yes
Hypoxia is a common feature of solid tumours and is associated with poor prognosis and resistance to therapy. Attempts to therapeutically target hypoxic tumour cells have shown limited clinical success. This thesis investigates the role of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine synthesis pathway (SSP), in hypoxic
openaire   +2 more sources

PHGDH regulates dendritic cell immune crosstalk 2267410

open access: yesThe Journal of Immunology
Abstract Introduction Conventional dendritic cells (cDCs) play a unique role in immunoregulation and antigen presentation, which is fundamental to protective immunity and is implicated in various autoimmune pathologies.
Ebenezer Asiedu, Connie Krawczyk
openaire   +2 more sources

MAPK13 phosphorylates PHGDH and promotes its degradation via chaperone-mediated autophagy during liver injury

open access: yesCell Discovery
Drug-induced liver injury (DILI) is the leading cause of acute liver failure and poses a significant clinical challenge in both diagnosis and treatment.
Ru Xing   +6 more
doaj   +2 more sources

Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profiling

open access: yesActa Pharmaceutica Sinica B, 2022
The first rate-limiting enzyme of the serine synthesis pathway (SSP), phosphoglycerate dehydrogenase (PHGDH), is hyperactive in multiple tumors, which leads to the activation of SSP and promotes tumorigenesis. However, only a few inhibitors of PHGDH have
Chen Chen   +9 more
doaj   +1 more source

Phosphoglycerate dehydrogenase positively regulates the proliferation of chicken muscle cells

open access: yesPoultry Science, 2022
: Phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme in the serine synthesis pathway. However, the regulatory role of PHGDH in muscle development is unclear.
Han Wang   +7 more
doaj   +1 more source

Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma

open access: yesBMC Medical Genomics, 2023
Background PHGDH (Phosphoglycerate Dehydrogenase) is the first branch enzyme in the serine biosynthetic pathway and plays a vital role in several cancers. However, little is known about the clinical significance of PHGDH in endometrial cancer.
He Zhang   +5 more
doaj   +1 more source

Phgdh acted as another tipping point signature.

open access: yes, 2023
Related to Fig 4. (A) The schematic diagram showing the in vitro flow assay in Cas9 expressing HSPCs infected with Myc-GFP and sgRNA-mCherry. (B) T7 endonuclease I assay showed the sgNpm1/Phgdh efficiency in c-Kit+ cells derived from Cas9 expressing ...
Chong Chen (360710)   +17 more
core   +1 more source

Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis

open access: yesCell Reports, 2020
Summary: Phosphoglycerate dehydrogenase (PHGDH) is the first enzyme in the serine synthesis pathway in which it is also the rate-limiting enzyme. It is significantly upregulated in many cancers, especially breast cancer.
Chao Wang   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy